Razadyne generic wins FDA approval - - Modern MedicineAllergy ImmunologyCardiovascular DiseaseClinical Pharmacology Cosmetic SurgeryDermatologyEndocrinologyGastroenterologyGeriatricsInfectious DiseaseInternal MedicineLocum TenensBarr Pharmaceuticals Inc., recently announced that its subsidiary, Barr Laboratories Inc., received final approval from the U.S. Food and Drug Administration for a generic version of Razadyne ER, Ortho McNeilJanssen's galantamine hydrobromide extended release capsules. Galantamine, a tertiary alkaloid, is a competitive and reversible acetylcholinesterase inhibitor. "Assuming the price is less than any of the branded drugs in this class, generic Razadyne ER will be a more cost-effective option for most patients who respond to cholinesterase inhibitors. Having a less expensive cholinesterase inhibitor available likely will make it the first-choice agent in the class for patients just being started on cognitive therapy, since there is no way to tell which drug in this class the patient is most likely to respond to," Robert J. Cluxton Jr., PharmD, MBA, CGP, said. Cluxton is Professor of Pharmacy Practice and Family Medicine at the James L. Winkle College of Pharmacy, University of Cincinnati.
